HT-01
Prevention of Graft-versus-Host Disease (GvHD) post bone marrow transplant
Pre-clinicalActive
Key Facts
Indication
Prevention of Graft-versus-Host Disease (GvHD) post bone marrow transplant
Phase
Pre-clinical
Status
Active
Company
About HasenTech
HasenTech is a private, preclinical-stage biotech developing HT-01, a novel exopolysaccharide (EPS) therapy to make bone marrow transplants safer by preventing Graft-versus-Host Disease (GvHD). The company's foundational IP is based on research from the University of Massachusetts, with a patent issued in 2019. Led by a seasoned team with a prior successful exit (Hematech), HasenTech aims to address a significant unmet need in transplant medicine and expand into broader inflammatory and autoimmune conditions.
View full company profile